Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone

Jörg B. Engel, Gunhild Keller, Andrew V. Schally, Gabor L. Toller, Kate Groot, Alexandre Havt, Patricia Armatis, Marta Zarandi, Jozsef L. Varga, Gabor Halmos

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

Antagonists of GHRH are being developed for the treatment of various cancers. In this study we investigated in vivo and in vitro the effects of the GHRH antagonist MZ-J-7-118 and its mechanism of action in HEC-1A human endometrial cancer. Treatment of nude mice bearing HEC-1A xenografts with 10 μg/d MZ-J-7-118 for 6 wk significantly inhibited the volume of HEC-1A tumors by 43%, tumor weight by 40% compared with controls and prolonged the tumor doubling time from 18.7 ± 1.4 to 25.4 ± 3.8 d. Administration of 20 μg MZ-J-7-118, sc, twice a day significantly (P < 0.05) decreased HEC-1A growth, as evidenced by a 57.9% decrease in tumor volume, a 50.7% reduction in tumor weight, and the extension of tumor doubling time from 17.5 ± 2.8 to 36.4 ± 6.5 d. Therapy with GHRH antagonists significantly decreased serum IGF-I levels in experiment 1, and significantly increased tumoral IGF-I levels in experiment 2 in treated mice. Levels of IGF-II and vascular endothelial growth factor-A in tumors were not changed. Specific high affinity binding sites for GHRH were found on HEC-1A tumor membranes using ligand competition assays with 125I-labeled GHRH antagonist JV-1-42. MZ-J-7-118 displaced radiolabeled JV-1-42 with an IC50 of 0.13 ± 0.04 nM. The expression of mRNA for GHRH and splice variants of the GHRH receptor in HEC-1A tumors was demonstrated by real-time RT-PCR analysis. HEC-1A cells cultured in vitro secreted GHRH into the medium. The GHRH antagonist MZ-J-7-118 inhibited the growth of HEC-1A cells in vitro. Our results indicate that GHRH antagonists can reduce the growth of human endometrial cancer and could be used as an alternative adjuvant therapy for the management of endometrial cancer.

Original languageEnglish (US)
Pages (from-to)3614-3621
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Volume90
Issue number6
DOIs
StatePublished - Jun 1 2005
Externally publishedYes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone'. Together they form a unique fingerprint.

  • Cite this

    Engel, J. B., Keller, G., Schally, A. V., Toller, G. L., Groot, K., Havt, A., Armatis, P., Zarandi, M., Varga, J. L., & Halmos, G. (2005). Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone. Journal of Clinical Endocrinology and Metabolism, 90(6), 3614-3621. https://doi.org/10.1210/jc.2004-2179